# **Special Issue**

# State of the Art on PET/CT and PET/MRI in Oncology

# Message from the Guest Editor

The advancing development of personalized therapeutic concepts in the oncological context benefits from image-based precision medicine, where PET/CT and PET/MRI have proven to be valuable techniques for the early detection and precise localization of tumor lesions. accurate determination of tumor stage, and monitoring treatment response. With the ongoing development of individualized molecular therapy concepts, hybrid imaging has been gaining increasing diagnostic and clinical importance, as it provides the highest possible imaging information content compared to other radiological and nuclear medicine modalities. In addition, the exploration of various radiopharmaceutical agents has opened up novel possibilities for the in vivo molecular characterization of cancer. This Special Issue aims to highlight the role of hybrid imaging in cancer management, such as individualized diagnosis and therapeutic biomarker drug assessment, to provide clinicians with information to assist in the development of optimal treatment options for cancer. Therefore, we encourage researchers in the field to submit original articles and review papers to this Special Issue.

## **Guest Editor**

Dr. Christian Philipp Reinert

Department of Radiology, Diagnostic and Interventional Radiology, University Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany

## Deadline for manuscript submissions

closed (1 June 2024)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/174995

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



# About the Journal

# Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

#### Editor-in-Chief

#### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

#### **Author Benefits**

# **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

